Showing results (151-160 of 192) with videos related to

Sort By:
Pageof 20
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 28, 2018
Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1Susanna A McColley, Michael W Konstan, Bonnie W Ramsey, et al.
Indoor Air|March 18, 2017
Sources and dynamics of fluorescent particles in hospitalsM L Pereira, L D Knibbs, C He, et al.
Antimicrobial Agents and Chemotherapy|September 12, 2018
Expression of Pseudomonas aeruginosa Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis PatientsLois W Martin, Cynthia L Robson, Annabelle M Watts, et al.
BMC Infectious Diseases|June 7, 2014
A comparison of two informative SNP-based strategies for typing Pseudomonas aeruginosa isolates from patients with cystic fibrosisMelanie W Syrmis, Timothy J Kidd, Ralf J Moser, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 22, 2022
A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variantGregory S Sawicki, Mark Chilvers, John McNamara, et al.
Thorax|April 30, 2021
Time to get serious about the detection and monitoring of early lung disease in cystic fibrosisKatie J Bayfield, Tonia A Douglas, Tim Rosenow, et al.
The European Respiratory Journal|August 11, 2012
Shared Pseudomonas aeruginosa genotypes are common in Australian cystic fibrosis centresTimothy J Kidd, Kay A Ramsay, Honghua Hu, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 28, 2022
Factors in childhood associated with lung function decline to adolescence in cystic fibrosisNelufa Begum, Catherine A Byrnes, Joyce Cheney, et al.
Pageof 20